Stock Track | Summit Therapeutics Soars 5.42% Intraday on Citi Buy Rating and ASCO Catalyst Expectations

Stock Track

05/04

Summit Therapeutics PLC's stock surged 5.42% during intraday trading on Monday, marking a significant rebound.

The rally is attributed to renewed market confidence following Citi analyst Yigal Nochomovitz maintaining a Buy rating and a $40 price target on the stock, despite recent adverse clinical trial data. Additionally, investor optimism is building ahead of the upcoming ASCO conference, where the company's partner Akeso Biopharma is scheduled to present overall survival data for ivonescimab from the HARMONi-6 trial, seen as a potential near-term positive catalyst.

This upward move represents a recovery from a recent sharp decline triggered by interim trial data and a weak quarterly financial report. The company also noted that final progression-free survival results from the HARMONi-3 trial are expected later this year.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1184566905"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1184566905\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1184566905?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-04 21:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184566905","market":"sg","top_or_hot":-1,"title":"Stock Track | Summit Therapeutics Soars 5.42% Intraday on Citi Buy Rating and ASCO Catalyst Expectations","media":"Stock Track","content":"<p>Summit Therapeutics PLC's stock surged 5.42% during intraday trading on Monday, marking a significant rebound.</p><p>The rally is attributed to renewed market confidence following Citi analyst Yigal Nochomovitz maintaining a Buy rating and a $40 price target on the stock, despite recent adverse clinical trial data. Additionally, investor optimism is building ahead of the upcoming ASCO conference, where the company's partner Akeso Biopharma is scheduled to present overall survival data for ivonescimab from the HARMONi-6 trial, seen as a potential near-term positive catalyst.</p><p>This upward move represents a recovery from a recent sharp decline triggered by interim trial data and a weak quarterly financial report. The company also noted that final progression-free survival results from the HARMONi-3 trial are expected later this year.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Summit Therapeutics Soars 5.42% Intraday on Citi Buy Rating and ASCO Catalyst Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Summit Therapeutics Soars 5.42% Intraday on Citi Buy Rating and ASCO Catalyst Expectations\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-05-04 21:54</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Summit Therapeutics PLC's stock surged 5.42% during intraday trading on Monday, marking a significant rebound.</p><p>The rally is attributed to renewed market confidence following Citi analyst Yigal Nochomovitz maintaining a Buy rating and a $40 price target on the stock, despite recent adverse clinical trial data. Additionally, investor optimism is building ahead of the upcoming ASCO conference, where the company's partner Akeso Biopharma is scheduled to present overall survival data for ivonescimab from the HARMONi-6 trial, seen as a potential near-term positive catalyst.</p><p>This upward move represents a recovery from a recent sharp decline triggered by interim trial data and a weak quarterly financial report. The company also noted that final progression-free survival results from the HARMONi-3 trial are expected later this year.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SMMT","symbol_name":"Summit Therapeutics PLC","start_time":0,"source_url":"","article_id":"1184566905","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184566905","pubTimestamp":1777902888,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Summit Therapeutics PLC's stock surged 5.42% during intraday trading on Monday, marking a significant rebound.The rally is attributed to renewed market confidence following Citi analyst Yigal...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SMMT":"Summit Therapeutics PLC"},"translate_title":"个股追踪|Summit Therapeutics盘中大涨5.42%，受花旗买入评级和ASCO催化剂预期影响","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMT":1},"content_text":"Summit Therapeutics PLC's stock surged 5.42% during intraday trading on Monday, marking a significant rebound.The rally is attributed to renewed market confidence following Citi analyst Yigal Nochomovitz maintaining a Buy rating and a $40 price target on the stock, despite recent adverse clinical trial data. Additionally, investor optimism is building ahead of the upcoming ASCO conference, where the company's partner Akeso Biopharma is scheduled to present overall survival data for ivonescimab from the HARMONi-6 trial, seen as a potential near-term positive catalyst.This upward move represents a recovery from a recent sharp decline triggered by interim trial data and a weak quarterly financial report. The company also noted that final progression-free survival results from the HARMONi-3 trial are expected later this year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}